Gee S, Taylor D
CNS Drugs. 2022; 36(2):105-111.
PMID: 35113345
DOI: 10.1007/s40263-022-00900-w.
Gee S, McMullen I, Wyke C, Yeoh S, Taylor D
SAGE Open Med Case Rep. 2021; 9:2050313X211004796.
PMID: 34094561
PMC: 8141995.
DOI: 10.1177/2050313X211004796.
Albitar O, Harun S, Zainal H, Ibrahim B, Sheikh Ghadzi S
Biomed Res Int. 2020; 2020:9872936.
PMID: 31998804
PMC: 6970501.
DOI: 10.1155/2020/9872936.
Mauri M, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I
Clin Pharmacokinet. 2018; 57(12):1493-1528.
PMID: 29915922
DOI: 10.1007/s40262-018-0664-3.
Park H, Kim E, Moon B, Lim N, Lee B, Kim S
CPT Pharmacometrics Syst Pharmacol. 2015; 4(5):305-11.
PMID: 26225256
PMC: 4452936.
DOI: 10.1002/psp4.38.
Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.
Moreno J, Holloway T, Umali A, Rayannavar V, Sealfon S, Gonzalez-Maeso J
Psychopharmacology (Berl). 2012; 225(1):217-26.
PMID: 22842765
PMC: 3552490.
DOI: 10.1007/s00213-012-2809-7.
A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment.
Guitton C, Kinowski J, Gomeni R, Bressolle F
Clin Drug Investig. 2008; 16(1):35-43.
PMID: 18370516
DOI: 10.2165/00044011-199816010-00005.
Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Mauri M, Volonteri L, Colasanti A, Fiorentini A, De Gaspari I, Bareggi S
Clin Pharmacokinet. 2007; 46(5):359-88.
PMID: 17465637
DOI: 10.2165/00003088-200746050-00001.
What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.
Schulte P
Clin Pharmacokinet. 2003; 42(7):607-18.
PMID: 12844323
DOI: 10.2165/00003088-200342070-00001.
Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes.
Fang J
Eur J Drug Metab Pharmacokinet. 2000; 25(2):109-14.
PMID: 11112091
DOI: 10.1007/BF03190076.
Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.
Fang J, Gorrod J
Cell Mol Neurobiol. 1999; 19(4):491-510.
PMID: 10379422
PMC: 11545447.
DOI: 10.1023/a:1006938908284.
Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
Fitton A, Benfield P
Pharmacoeconomics. 1993; 4(2):131-56.
PMID: 10146973
DOI: 10.2165/00019053-199304020-00007.
Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.
Olesen O
Clin Pharmacokinet. 1998; 34(6):497-502.
PMID: 9646010
DOI: 10.2165/00003088-199834060-00005.
Will routine therapeutic drug monitoring have a place in clozapine therapy?.
Freeman D, Oyewumi L
Clin Pharmacokinet. 1997; 32(2):93-100.
PMID: 9068925
DOI: 10.2165/00003088-199732020-00001.
Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.
Fabrazzo M, Esposito G, Fusco R, Maj M
Psychopharmacology (Berl). 1996; 124(1-2):197-200.
PMID: 8935816
DOI: 10.1007/BF02245621.
CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.
Nordin C, Alme B, Bondesson U
Psychopharmacology (Berl). 1995; 122(2):104-7.
PMID: 8848524
DOI: 10.1007/BF02246083.
Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.
Korpi E, Wong G, Luddens H
Naunyn Schmiedebergs Arch Pharmacol. 1995; 352(4):365-73.
PMID: 8532064
DOI: 10.1007/BF00172773.
Pharmacokinetics and pharmacodynamics of clozapine.
Jann M, Grimsley S, Gray E, Chang W
Clin Pharmacokinet. 1993; 24(2):161-76.
PMID: 8453823
DOI: 10.2165/00003088-199324020-00005.
Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
Dahl M, Llerena A, Bondesson U, Lindstrom L, Bertilsson L
Br J Clin Pharmacol. 1994; 37(1):71-4.
PMID: 8148222
PMC: 1364713.
DOI: 10.1111/j.1365-2125.1994.tb04242.x.
Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study.
Olesen O, Thomsen K, JENSEN P, Wulff C, Rasmussen N, Refshammer C
Psychopharmacology (Berl). 1995; 117(3):371-8.
PMID: 7770613
DOI: 10.1007/BF02246112.